Company intelligence / Profile preview

EraCal Therapeutics

Schlieren, Zurich, Switzerlanderacal.ch ↗

Ownership: Private
Development stage: Preclinical

Overview

EraCal’s lead compound, Era-379, demonstrated >20% body weight reduction in obese mice upon oral dosing. The company’s approach represents a new mode of action for appetite suppression. In January 2024, the program was outlicensed to Novo Nordisk for €235M plus royalties. No human clinical results are publicly available.

Therapeutic areas: Metabolic Disorders
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

ERA-379

Pre-clinical

Indications: Obesity

Partnerships

Novo Nordisk (outlicensing deal for lead asset)research collaboration with Novo Nordisk

Beyond the preview

Go deeper on EraCal Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EraCal Therapeutics.

Explore the full profile